secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIPELLA PHARMACEUTICALS INC. (LIPO)
CIK:        0001347242
Form:       8-K
Filed at:   2025-01-06T23:59:59+00:00
Accession:  0001753926-25-000035
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipella raises $368K in second closing of Series B preferred offering; CEO gets voting proxy
--------------------------------------------------------------------------------

- Second closing issued 3,680 shares of Series B non-voting convertible preferred at $100/share, convertible into 117,948 common shares at $3.12/share.
- Net proceeds of $305,440; use for working capital and general corporate purposes.
- Placement agent Spartan received $62,560 in fees, 42,933 Series C voting preferred shares, and a warrant for 11,795 common shares.
- Spartan granted CEO Jonathan Kaufman irrevocable voting power over all Series C and warrant shares via proxy agreement.
- Total offering remains open up to $6.0 million; first closing on Dec 30 sold 22,295 Series B shares for $2.23M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347242/000175392625000035/0001753926-25-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347242/000175392625000035/g084643_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer